Phacilitate Leaders World

Sponsors & Exhibitors

Oxford BioMedica

Oxford BioMedica is a leading gene-based biopharmaceutical company developing innovative medicines to improve the lives of patients with high unmet medical needs. We have established platform technologies in gene delivery and immunotherapy, protected by an extensive intellectual property estate. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and is also widely used in the ex-vivo cell therapy arena.

Oxford BioMedica's product portfolio is focused on high value, growing markets. These include gene therapy products engineered to treat Parkinson's disease (preclinical, Phase I/II), Motor Neurone Disease (preclinical) and ocular diseases (preclinical), especially retinal diseases (Phase I and Phase I/II).

The Company also has a MHRA certified GMP manufacturing capability to produce Advanced Medicinal Products (AMP). In particular our focus is on viral manufacturing and development.

Visit Website
View all Sponsors & Exhibitors
Loading
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK